HOME Research Insight New Product Launches, Acquisitions, Collaborations, and Partnerships Are the Driving Factors for the U.S. Insomnia Market

New Product Launches, Acquisitions, Collaborations, and Partnerships Are the Driving Factors for the U.S. Insomnia Market

Some of the major players in the U.S. insomnia market include Eisai, Co. Ltd. (Japan), Merck & Co., Inc (U.S.), Meda Consumer Healthcare Inc (U.S.), Pfizer, Inc (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), and Purdue Pharma L.P. (U.S.).

The insomnia market is currently crowded with generic medicine as the key brands face extensive generic competition. Also these key brands do not have any pipeline products to counter the decline in the sales. Once top selling drug Ambien (Sanofi) and Lunesta (Sunovion Pharmaceuticals) now face generic competition.

To compete in the crowded insomnia market, the key players focus on development of products with new mechanisms of action, reformulations of generically available drugs, and strategic partnerships between companies. For instance, in February 2015, Merck & Co., Inc launched Belsomra, a first-in-class prescription sleep aid; an orexin receptor antagonist unlike other insomnia drugs present in the market. E-2006 from Eisai Co., Ltd. is another orexin receptor antagonist currently undergoing clinical trials. Orexin receptor antagonists is a novel drug and this would enable future players to differentiate their products from other drugs/treatments available in the market and gain market share.

Other strategies witnessed within insomnia market include companies entering licensing agreements for the development and marketing of insomnia products, acquisition of promising late-stage pipeline assets from smaller firms, and partnership with academia to accelerate development of new drug therapies. For instance, in August 2015, Eisai Co., Ltd., entered into a collaboration with Purdue Pharma L.P. (U.S.) for the development and commercialization of Eisai’s product E2006 (lemborexant) which is in the Phase III of the clinical development. In March 2013, Pernix Therapeutics acquired Somaxon Pharmaceuticals, Inc. (U.S.). This acquisition led to the addition of insomnia drug Silenor (doxepin) to Pernix’s product portfolio. Hence, these strategies help companies to share the ongoing research and development costs, utilise combines resources and geographic presence, and maximising the commercial reach for products in the insomnia market.

Related Reports:

U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021

UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support

US : 1-888-600-6441

Search reports